Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, gives an overview of on-target and off-target side effects from anticancer targeted agents.
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, gives an overview of on-target and off-target side effects from anticancer targeted agents.
On-target side effects refer to the pharmacodynamic effect on normal tissues that occurs when the target that's being inhibited in the tumor is also being inhibited in the normal tissue. Common on-target side effects include skin rash from inhibitors of the MAP kinase pathway or ocular toxicities from MEK inhibitors, Hsp90 inhibitors, and selective FGFR inhibitors.
Off-target side effects are unexpected and are due to the effects from other targets or the structure of the drug.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More